JP2021530501A5 - - Google Patents

Info

Publication number
JP2021530501A5
JP2021530501A5 JP2021500920A JP2021500920A JP2021530501A5 JP 2021530501 A5 JP2021530501 A5 JP 2021530501A5 JP 2021500920 A JP2021500920 A JP 2021500920A JP 2021500920 A JP2021500920 A JP 2021500920A JP 2021530501 A5 JP2021530501 A5 JP 2021530501A5
Authority
JP
Japan
Prior art keywords
apmv
nucleotide sequence
sequence encoding
pharmaceutical composition
recombinant
Prior art date
Application number
JP2021500920A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020014591A5 (https=
JP2021530501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041568 external-priority patent/WO2020014591A1/en
Publication of JP2021530501A publication Critical patent/JP2021530501A/ja
Publication of JPWO2020014591A5 publication Critical patent/JPWO2020014591A5/ja
Publication of JP2021530501A5 publication Critical patent/JP2021530501A5/ja
Pending legal-status Critical Current

Links

JP2021500920A 2018-07-13 2019-07-12 癌の治療のためのａｐｍｖ及びその使用 Pending JP2021530501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697944P 2018-07-13 2018-07-13
US62/697,944 2018-07-13
PCT/US2019/041568 WO2020014591A1 (en) 2018-07-13 2019-07-12 Apmv and uses thereof for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2021530501A JP2021530501A (ja) 2021-11-11
JPWO2020014591A5 JPWO2020014591A5 (https=) 2022-07-26
JP2021530501A5 true JP2021530501A5 (https=) 2022-07-26

Family

ID=69141914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500920A Pending JP2021530501A (ja) 2018-07-13 2019-07-12 癌の治療のためのａｐｍｖ及びその使用

Country Status (6)

Country Link
US (2) US20200297787A1 (https=)
EP (1) EP3820492A4 (https=)
JP (1) JP2021530501A (https=)
CN (1) CN112739359A (https=)
CA (1) CA3106170A1 (https=)
WO (1) WO2020014591A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2021174121A1 (en) * 2020-02-27 2021-09-02 Icahn School Of Medicine At Mount Sinai Vegfr-3-activating agents and oncolytic viruses and uses thereof for the treatment of cancer
WO2022067038A1 (en) * 2020-09-25 2022-03-31 President And Fellows Of Harvard College Immunotherapeutic virus for the treatment of cancer
US20240199705A1 (en) * 2021-04-26 2024-06-20 Icahn School Of Medicine At Mount Sinai Chimeric newcastle disease virus expressing apmv hn and f proteins
CN117925916A (zh) * 2024-03-11 2024-04-26 广州市金域转化医学研究院有限公司 Hpv dna的e6基因在制备浸润性宫颈癌诊断产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
BRPI0517834A (pt) * 2004-11-12 2008-10-21 Bayer Schering Pharma Ag vìrus da doença de newcastle recombinante
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
HUE053237T2 (hu) * 2009-08-21 2021-06-28 Boehringer Ingelheim Animal Health Usa Inc Rekombináns madárparamixovírus-vakcina és eljárás elõállítására és alkalmazására
EP2579884B1 (en) * 2010-06-10 2014-06-04 Intervet International B.V. Anti-tumor composition
EA038981B1 (ru) * 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
WO2015032755A1 (en) * 2013-09-03 2015-03-12 Medimmune Limited Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Similar Documents

Publication Publication Date Title
JP2021530501A5 (https=)
US20240058383A1 (en) Adoptive cell transfer and oncolytic virus combination therapy
Chaurasiya et al. Oncolytic viruses and immunity
CN108635380A (zh) 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
JP2016513115A5 (https=)
CN108841796A (zh) 重组单纯疱疹病毒及其制备方法和应用
JP7239910B2 (ja) 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用
Williams et al. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
EP3455350A1 (en) Combination prime: boost therapy
Malfitano et al. Virotherapy as a potential therapeutic approach for the treatment of aggressive thyroid cancer
CN105031630A (zh) 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法
CN105177045A (zh) 表达人白介素15的重组溶瘤腺病毒及其构建方法
Jindra et al. Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients
Ip et al. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines
Sokke Umeshappa et al. CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination
Jiang et al. Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors
JP2021522190A (ja) 腫瘍を治療するためのコクサッキーウイルスｂ群
Hatami et al. Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype
JPWO2020014591A5 (https=)
CN119736337A (zh) Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗
Letafati et al. Oncolytic viruses against cancer, promising or delusion?
CN104583410A (zh) 同时表达猪α干扰素和猪γ干扰素的重组腺病毒
TWI259206B (en) A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof
JP2013529082A (ja) 遺伝子組み換えｒｓウイルスを使用した乳がん治療